Dostarlimab Demonstrates Promising Response Rates in Advanced ...

OncLive - 08 Jun 2022
Single-agent dostarlimab generated durable antitumor activity in patients with advanced or recurrent endometrial cancer with mismatch repair ...

Dostarlimab/Chemo Yields “Unprecedented” OS in dMMR Endometrial Cancer

Cancer Network - 20 Mar 2024
Dostarlimab/Chemo Yields “Unprecedented” OS in dMMR Endometrial Cancer ...

FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat Endometrial Cancer

Pharmacy Times - 25 Apr 2024
FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat Endometrial Cancer ...

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell ...

Nature.com - 11 Nov 2023
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell ... ...

NICE Recommends Dostarlimab Plus Chemo in MSI-High/dMMR Endometrial Cancer

OncLive - 05 Mar 2024
NICE Recommends Dostarlimab Plus Chemo in MSI-High/dMMR Endometrial Cancer ...

Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer

ScienceDirect.com - 18 Oct 2023
Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer ...

Dostarlimab given NICE go-ahead in first-line combination treatment for endometrial cancer

Hospital Healthcare - 14 Mar 2024
Dostarlimab given NICE go-ahead in first-line combination treatment for endometrial cancer ...

Jemperli (dostarlimab-gxly) to Treat Advanced Solid Tumours

Clinical Trials Arena - 29 Sep 2023
Jemperli (dostarlimab-gxly) to Treat Advanced Solid Tumours ...

Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers

Cancer Network - 24 Apr 2024
Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers ...

Immune Checkpoint Inhibitor-Chemo Combo Boosts OS in Advanced Endometrial Cancer

Medpage Today - 17 Mar 2024
Immune Checkpoint Inhibitor-Chemo Combo Boosts OS in Advanced Endometrial Cancer ...

Dostarlimab, Chemotherapy Combo Is Cost Effective, Improves QOL for Endometrial Cancer Patients

DocWire News - 24 Apr 2024
Dostarlimab, Chemotherapy Combo Is Cost Effective, Improves QOL for Endometrial Cancer Patients ...

Behind the RUBY Trial of Dostarlimab and Chemo for Endometrial Cancer

Targeted Oncology - 24 Jan 2024
Behind the RUBY Trial of Dostarlimab and Chemo for Endometrial Cancer ...

Dostarlimab Plus Chemo Followed by Dostarlimab/Niraparib Improves PFS in Endometrial Cancer

OncLive - 20 Dec 2023
Dostarlimab Plus Chemo Followed by Dostarlimab/Niraparib Improves PFS in Endometrial Cancer ...

Overall Survival in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Dostarlimab Plus ...

OncLive - 29 Mar 2024
Overall Survival in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Dostarlimab Plus ... ...

Dostarlimab/Chemo Earns Positive CHMP Opinion in Advanced Endometrial Cancer

Cancer Network - 26 Oct 2023
Dostarlimab/Chemo Earns Positive CHMP Opinion in Advanced Endometrial Cancer ...

Dostarlimab Plus Chemo Continues to Demonstrate Strong Clinical Efficacy in Advanced NSCLC

OncLive - 20 Oct 2023
Dostarlimab Plus Chemo Continues to Demonstrate Strong Clinical Efficacy in Advanced NSCLC ...

Dostarlimab/Niraparib Improves PFS Outcomes in Advanced Endometrial Cancer

Cancer Network - 20 Dec 2023
Dostarlimab/Niraparib Improves PFS Outcomes in Advanced Endometrial Cancer ...

CHMP Recommends Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced/Recurrent Endometrial Cancer

OncLive - 16 Oct 2023
CHMP Recommends Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced/Recurrent Endometrial Cancer ...

Dostarlimab Combo Significantly Improves PFS in Advanced Endometrial Cancer

Cancer Network - 16 Nov 2023
Dostarlimab Combo Significantly Improves PFS in Advanced Endometrial Cancer ...

Cobolimab/Dostarlimab Combination Shows Initial Efficacy and Safety Signals in Advanced NSCLC

OncLive - 10 Jan 2024
Cobolimab/Dostarlimab Combination Shows Initial Efficacy and Safety Signals in Advanced NSCLC ...

Dostarlimab